Mitomycin is administered intravenously as monochemotherapy or in combined cytostatic chemotherapy in the case of advanced metastatic gastric carcinoma.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
5 - 10 mg per m² of body surface area (BSA)
From 5 To 10 mg per m² of body surface area (BSA) once every 14 day(s)
In cytostatic monochemotherapy mitomycin is usually administered intravenously as a bolus injection. The recommended dosage is 5-10 mg/m² of body surface every 1-6 weeks, depending on the therapeutic scheme used.
A dose greater than 20 mg/m² gives more toxic manifestations without therapeutic benefits. The maximum cumulative dose of mitomycin is 60 mg/m².
In combination therapy the dosage is considerably lower. Because of the risk of additive myelotoxicity, proven treatment protocols may not be deviated from without a specific reason.
Bolus injection.
Intravenous
10 - 20 mg per m² of body surface area (BSA)
From 10 To 20 mg per m² of body surface area (BSA) once every 42 day(s)
In cytostatic monochemotherapy mitomycin is usually administered intravenously as a bolus injection. The recommended dosage is 10-20 mg/m² of body surface every 6-8 weeks, depending on the therapeutic scheme used.
A dose greater than 20 mg/m² gives more toxic manifestations without therapeutic benefits. The maximum cumulative dose of mitomycin is 60 mg/m².
In combination therapy the dosage is considerably lower. Because of the risk of additive myelotoxicity, proven treatment protocols may not be deviated from without a specific reason.
Bolus injection.
Intravenous
8 - 12 mg per m² of body surface area (BSA)
From 8 To 12 mg per m² of body surface area (BSA) once every 28 day(s)
In cytostatic monochemotherapy mitomycin is usually administered intravenously as a bolus injection. The recommended dosage is 8-12 mg/m² of body surface every 3-4 weeks, depending on the therapeutic scheme used.
A dose greater than 20 mg/m² gives more toxic manifestations without therapeutic benefits. The maximum cumulative dose of mitomycin is 60 mg/m².
In combination therapy the dosage is considerably lower. Because of the risk of additive myelotoxicity, proven treatment protocols may not be deviated from without a specific reason.
Bolus injection.